Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, promoting insulin release and decreasing glucagon secretion in a glucose-dependent manner. It is unique among DPP-4 inhibitors as its primary route of elimination is biliary/fecal rather than renal. ## Primary Indications Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and effectiveness in pediatric patients under 18 years of age have not been established. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. * **Hepatic Impairment:** No dose adjustment required. * **Concomitant use with strong CYP3A4/P-gp inducers:** The efficacy of linagliptin may be reduced. If an inducer (e.g., rifampin) must be used, consider alternative glucose-lowering therapy. ## Contraindications * History of hypersensitivity reaction (e.g., anaphylaxis, angioedema, urticaria) to linagliptin. ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or sulfonylureas). * **Serious:** Acute pancreatitis (post-marketing reports), bullous pemphigoid, severe arthralgia, hypersensitivity reactions (angioedema, Stevens-Johnson syndrome). ## Key Drug Interactions * **Strong P-gp/CYP3A4 Inducers (e.g., Rifampin):** May decrease plasma concentrations of linagliptin, potentially reducing efficacy. * **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; dose reduction of the secretagogue or insulin may be required. ## Monitoring * **HbA1c:** Typically every 3–6 months. * **Blood Glucose:** For self-monitoring or when hypoglycemia is suspected. * **Clinical observation:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and severe skin reactions (blistering or erosions). ## Clinical Pearls * **Excretion:** Unlike other DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin), linagliptin does not require dosage adjustment for patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD). * **Heart Failure:** While saxagliptin and alogliptin have warnings regarding heart failure exacerbation, this risk is not currently associated with linagliptin. * **Pancreatitis:** If pancreatitis is suspected, discontinue linagliptin promptly. *** *Disclaimer: This information is for educational purposes and does not replace the professional judgment of a healthcare provider. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering any medication.*